Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Inclusion Criteria

• •1\. Age \> 18 years
• •2\. Diagnosis of ATTR cardiac amyloidosis (wild-type or V142I ATTR mutation)
• •a. Diagnosis of ATTR cardiac amyloidosis by established consensus diagnostic criteria of Gillmore et al. (either invasive or non-invasive diagnostic pathways)
• •3\. Plan for initiation of tafamidis therapy for clinical indications and agree to continue tafamidis during the duration of the study.
• •4\. Stated willingness to comply with all study procedures and availability for the duration of the study
• •5\. Able to understand and sign the informed consent document after the nature of the study has been fully explained.
• •6\. Women of childbearing potential who are sexually active with a non-sterilized male partner and males who are sexually active with a partner of childbearing potential must agree to use adequate contraception from screening until 30 days after the Flutemetamol.